Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LO LINYAH.
TRI LO SPRINTEC vs TRI-LO-LINYAH
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
Prevention of pregnancy
FDA-approved: Prevention of pregnancy.Off-label: Treatment of acne vulgaris, dysmenorrhea, menorrhagia, endometriosis-related pain, polycystic ovary syndrome (PCOS), menstrual cycle regulation.
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Hepatic metabolism via CYP3A4 isoenzymes; ethinyl estradiol undergoes conjugation (sulfation and glucuronidation), while norgestimate is rapidly deacetylated to norelgestromin (active metabolite) and further hydroxylated and conjugated.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 99% bound to albumin and alpha-1-acid glycoprotein.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Vd: 0.8-1.2 L/kg, indicating extensive tissue distribution.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: 80-90% (high bioavailability).
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment or end-stage renal disease; use with caution due to potential fluid and electrolyte changes.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Use caution in Child-Pugh class A or B; start with lowest effective dose if benefits outweigh risks, as steroids may be less well metabolized.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Approved for postmenarchal adolescents; dosing same as adults. Safety and efficacy in premenarchal patients not established.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for use in postmenopausal women. No specific dose adjustment studies; use generally avoided due to increased risk of thromboembolism and cardiovascular events.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from combined oral contraceptive use. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use combined oral contraceptives should be strongly advised not to smoke.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
["Increased risk of thromboembolic disorders (venous and arterial), especially in smokers, obesity, hypertension, or hyperlipidemia.","Elevated risk of hepatic neoplasia (benign and malignant).","Worsening of depression, migraine, or glucose tolerance.","May cause fluid retention, hypertension, irregular bleeding, or amenorrhea.","Cessation if jaundice, visual disturbances, or thrombotic events occur."]
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
["History of or current venous/arterial thromboembolic events (e.g., DVT, PE, stroke, MI).","Known thrombophilic disorders (e.g., factor V Leiden, prothrombin mutation).","Cerebrovascular or coronary artery disease.","Uncontrolled hypertension (BP >160/100 mmHg).","Diabetes with vascular involvement.","Migraine with focal aura (especially if age >35).","Active liver disease (e.g., hepatitis, cirrhosis) or hepatic tumors.","Known or suspected breast carcinoma or estrogen-dependent neoplasia.","Undiagnosed abnormal uterine bleeding.","Pregnancy or suspected pregnancy.","Hypersensitivity to any component.","Smoking in women >35 years (relative contraindication; absolute if heavy smoker).","Major surgery with prolonged immobilization (relative contraindication)."]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No significant food interactions. Grapefruit juice may modestly increase EE levels but not clinically relevant. St. John's Wort reduces contraceptive efficacy. High-fat meals may slightly delay absorption but does not affect overall exposure. Patients with lactose intolerance: contains lactose, may cause GI upset. Avoid excessive alcohol.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
Pregnancy Category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and limb defects, and increased risk of miscarriage. Use should be discontinued if pregnancy occurs.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Contraindicated in breastfeeding. Small amounts of hormonal contraceptives are excreted in breast milk; however, due to potential adverse effects on the nursing infant, use is not recommended. M/P ratio not established.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
No adjustments recommended; drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not relevant as use is contraindicated.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Lo-Linyah is a low-dose combination oral contraceptive containing ethinyl estradiol (EE) and norgestimate. It is indicated for pregnancy prevention. The 91-day extended regimen (84 active + 7 placebo) reduces withdrawal bleeding frequency. Counsel patients to take at the same time daily; missed pills increase breakthrough bleeding and pregnancy risk. Use with caution in smokers over 35, hypertension, migraine with aura, or history of thromboembolism. Consider alternative contraception in patients with liver disease or breast cancer. Prescribe as first-line for dysmenorrhea, menorrhagia, and menstrual regulation.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one tablet daily at the same time, even during bleeding. Missed pills require backup contraception.Use condoms initially for 7 days if starting for first time or after a break.Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding especially in first 3 months.Serious risks: blood clots (leg pain, chest, sudden SOB), stroke (vision/speech changes), liver tumors (abdominal pain).Do not smoke while on this pill; smoking greatly increases clotting risk.Antibiotics (except rifampin) and many anticonvulsants may reduce effectiveness; use backup.Keep pack away from heat/moisture; do not skip placebo pills.Consult healthcare provider before starting if you have migraine with aura, high blood pressure, or liver disease.